You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKesson
Harvard Business School
Medtronic
Johnson and Johnson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

ASTRAMORPH PF Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Astramorph Pf, and what generic alternatives are available?

Astramorph Pf is a drug marketed by Fresenius Kabi Usa and is included in four NDAs.

The generic ingredient in ASTRAMORPH PF is morphine sulfate. There are twenty-three drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Astramorph Pf

A generic version of ASTRAMORPH PF was approved as morphine sulfate by HOSPIRA on May 11th, 1988.

  Start Trial

Summary for ASTRAMORPH PF
Drug patent expirations by year for ASTRAMORPH PF
Recent Clinical Trials for ASTRAMORPH PF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute on Drug Abuse (NIDA)N/A
Vanderbilt University Medical CenterN/A
National Institutes of Health (NIH)Phase 4

See all ASTRAMORPH PF clinical trials

US Patents and Regulatory Information for ASTRAMORPH PF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa ASTRAMORPH PF morphine sulfate INJECTABLE;INJECTION 071050-001 Oct 7, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa ASTRAMORPH PF morphine sulfate INJECTABLE;INJECTION 071053-001 Oct 7, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa ASTRAMORPH PF morphine sulfate INJECTABLE;INJECTION 071051-001 Oct 7, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKesson
Harvard Business School
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.